Advance | $8,550,000 | (Feb 6, 2026)
Turnstile | $29,000,000 | (Feb 6, 2026)
Accrual | $75,000,000 | (Feb 6, 2026)
Certified by Founder
Lodge
CancerIQ
start up
United States
- Chicago, Illinois
- 04/03/2022
- Series B
- $14,000,000
About Us
CancerIQ helps providers use genetic information to predict, pre-empt, and prevent disease - starting with cancer. By making is easier to identify patients at risk, offer a genetic evaluation at point of care, and design a tailored cancer prevention plan - we can help healthcare systems get ahead of this costly and emotionally devastating disease.
Why Work with Us?
We have quietly built a market-leading product that patients, providers, and healthcare executives all love. With new funding and new strategic partners, we're on pace for rapid growth. We've a team of clever, scrappy, and mission-driven individuals making a huge impact in cancer prevention - so if you're passionate about healthcare - join our team.
- Industry Hospital & Health Care
- Website https://www.canceriq.com/
- LinkedIn https://www.linkedin.com/company/cancer-iq-inc-/about/
Connect Music | $80,000,000 | (Feb 6, 2026)
adaption | $50,000,000 | (Feb 6, 2026)
Cadastral | $9,500,000 | (Feb 6, 2026)
Nixtla | $16,000,000 | (Feb 6, 2026)
Nullify | $12,500,000 | (Feb 6, 2026)
Uplift360 | $8,724,008 | (Feb 6, 2026)
Fundamental | $255,000,000 | (Feb 6, 2026)
Duna | $35,365,500 | (Feb 6, 2026)
Flock AI | $6,000,000 | (Feb 6, 2026)